All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Ribociclib/Fulvestrant Combo Generates PFS Improvement in Metastatic Breast Cancer

May 23rd 2023

Ribociclib plus switch endocrine therapy induced a statistically significant progression-free survival benefit compared with placebo plus switch endocrine therapy in patients with hormone receptor–positive, HER2-negative, metastatic breast cancer.

China’s NMPA Accepts sNDA for Toripalimab Plus Chemo in Advanced TNBC

May 23rd 2023

The National Medical Products Administration has accepted the supplemental new drug application seeking the approval of toripalimab in combination with nab-paclitaxel in patients with untreated metastatic or recurrent triple-negative breast cancer and a PD-L1 combined positive score of at least 1.

SPEECH Conference Highlights Multiplicity of Ongoing Efforts in Cancer Care Equity

May 23rd 2023

Young investigators, fellows, and medical students recently gathered at the Temple University Lewis Katz School of Medicine in Philadelphia, Pennsylvania, to network and share exciting research aimed at addressing disparities in the dissemination of cancer care at the 5th Annual Regional Synergistic Partnership for Enhancing Equity in Cancer Health Conference and Retreat.

Sintilimab/Axitinib Combo Shrinks FH-Deficient RCC Tumors

May 23rd 2023

Xingming Zhang, MD, discusses unmet needs in fumarate hydratase–deficient renal cell carcinoma; shares key efficacy, safety, and quality of life findings from a phase 2 trial of sintilimab plus axitinib; and elaborates on the next steps for this research, including an analysis of biomarkers and potential resistance mechanisms.

Northwestern Medicine Successfully Performs Double-lung Transplant on a Second Patient With Stage 4 Lung Cancer and Launches First-of-its-kind Clinical Program

May 23rd 2023

For the second time at Northwestern Medicine, surgeons have successfully performed a double-lung transplant on a patient with stage 4 lung cancer who was being considered for hospice.

FDA Grants Priority Review to Lumisight Optical Imaging Agent for Breast Cancer Detection

May 23rd 2023

The FDA has granted priority review to a new drug application seeking the approval of the optical imaging agent Lumisight for use in patients with breast cancer, according to an announcement from Lumicell, Inc.

Health-Related QOL Differences Are Observed for Young Adults With CRC

May 23rd 2023

Amanda Bloomer, PhD, highlights the growing need for more research for this growing patient population and the age-specific findings that were seen in the ColoCare trial.

Advances Across Urothelial Carcinomas Highlight Need for Shared Decision-making

May 23rd 2023

As longer-term data read out for established regimens in urothelial cancer and up-and-coming therapeutics inch toward approval, optimizing treatment approaches relies on buy-in from multidisciplinary teams and patients.

NICE Recommends Pembrolizumab Plus Lenvatinib for Previously Treated Advanced or Recurrent Endometrial Cancer

May 22nd 2023

The National Institute for Health and Care Excellence has recommended the combination of pembrolizumab and lenvatinib for use in previously treated patients with advanced or recurrent endometrial cancer whose cancer has progressed on or after platinum-based chemotherapy and who cannot have curative surgery or radiotherapy.

FDA Approves Avapritinib for Indolent Systemic Mastocytosis

May 22nd 2023

The FDA has approved avapritinib (Ayvakit) for the treatment of adults with indolent systemic mastocytosis.

Investigation of CAR T-cell Therapy in Earlier Treatment Lines Could Continue to Alter Treatment Sequencing in Myeloma

May 22nd 2023

Faculty from an OncLive® Institutional Perspectives in Cancer webinar on multiple myeloma summarize the main messages from their presentations.

FDA Grants Orphan Drug Designation to Mitazalimab in Pancreatic Cancer

May 22nd 2023

The FDA has granted an orphan drug designation to mitazalimab for use as a potential therapeutic option in patients with pancreatic cancer.

GEN-002 Plus Avelumab Shows Promise as Third-line Option in PD-L1+ Gastric Cancer

May 22nd 2023

The combination of GEN-002 and avelumab elicited responses in patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to findings from an interim analysis of an ongoing phase 2 trial.

Milademetan Fails to Meet PFS End Point in Dedifferentiated Liposarcoma

May 22nd 2023

Treatment with milademetan did not lead to a statistically significant improvement in progression-free survival compared with trabectedin in patients with dedifferentiated liposarcoma, failing to reach the primary end point of the phase 3 MANTRA trial.

OncLive Honors 12 Cancer Care Pioneers

May 22nd 2023

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Dana-Farber Researchers Report on the Safety and Activity of Immune Checkpoint Inhibitors in People Living with HIV and Cancer

May 22nd 2023

People living with HIV remain at higher risk than people living without HIV for developing various cancers that can be treated with immune checkpoint inhibitors.

Retrospective Findings Show Younger Age of LGBTQI+ Patients at Time of Diagnosis

May 21st 2023

Shahrzad A. Zamani discusses the research on cancer disparities in patients within the LGBTQI+ population, and how these findings could inform further research and decisions in clinical practice.

Cabozantinib Plus Nivolumab and Ipilimumab Provides PFS Benefit in Advanced RCC

May 20th 2023

The addition of cabozantinib to nivolumab and ipilimumab led to improved progression-free survival vs nivolumab and ipilimumab alone in patients with treatment-naïve advanced renal cell carcinoma; however, the rate of grade 3/4 adverse effects with the triplet was 79%.

Analysis Determines Predictive Biomarkers for Lenalidomide Survival Benefits in Mantle Cell Lymphoma

May 19th 2023

Polymorphic alleles of ABCB1 or VEGF were predictive of lenalidomide efficacy in patients with mantle cell lymphoma who received lenalidomide maintenance after autologous stem cell transplant.

AEGEAN Trial Demonstrates Benefit and Viability of Novel Perioperative Treatment Approach in NSCLC

May 19th 2023

John V. Heymach, MD, PhD, expands on the efficacy of perioperative durvalumab in the AEGAN trial, the significance of this unique approach for the non–small cell lung cancer treatment paradigm, and future research examining opportunities to build on or intensify the benefit achieved with this regimen.